Lisa White, Professor of Modelling and Epidemiology at our MORU unit in Thailand, tells us how we can use mathematical and economic modelling to better use limited resources to control or eradicate tropical diseases Mathematical modelling, particularly when combined with economical modelling, allows researchers and policy makers to determine the most effective interventions to fight infectious diseases such as malaria. We can use those models to explore ‘what ifs’ scenarios, at country or province level, save more lives and limit costs.

Mathematical modelling for tropical diseases 

Professor Ric Price, affiliated with our OUCRU unit, tells us of his research on surveillance, diagnostics and treatments for Plasmodium vivax malaria Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Curing Plasmodium vivax malaria 

Professor Olivo Miotto from our MORU programme in Bangkok, Thailand, tells us how genomics can help us improve global health Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Genomics and global health 

Dr Rob van der Pluijm from MORU (Mahidol Oxford Research Unit) in Bangkok, Thailand, tells us about his work as project coordinator in mapping resistance to antimalarials Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.

Tracking antimalarial resistance and treatment of malaria using Triple ACTs 

Dr Andrea Ruecker from MORU (Mahidol Oxford Research Unit) in Bangkok, Thailand, talks about possible interventions to block the transmission of falciparum malaria In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

Blocking malaria transmission 

Professor Frank Smithuis from our MOCRU unit in Myanmar tells us about his research on malaria Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Fighting malaria in Myanmar 

Dr James Watson from MORU  in Bangkok, Thailand, tells us about his research in the biology of relapse in vivax malaria, as well as the development of statistical models to better understand the pharmacology of antimalarial drugs. Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

Primaquine and vivax malaria 

Dr Xin Hui Chan from MORU (Mahidol Oxford Research Unit) in Bangkok, Thailand, tells us about the use of big data in our efforts to eliminate malaria Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.

Using big data to eliminate malaria 

Dr Tom Peto from MORU (Mahidol Oxford Research Unit) in Bangkok, Thailand, tells us how mass drug administration can help eliminate malaria Although malaria has greatly declined in Southeast Asia this century, treating clinical cases won’t be sufficient to eliminate it from the region. Mass drug administration allows to eliminate parasites from asymptomatic carriers, and careful engagement with whole communities is key.

Malaria elimination and mass drug administration 

Dr Bob Taylor from MORU (Mahidol Oxford Research Unit) in Bangkok, Thailand, tells us about his research on malaria, and how we can use primaquine to treat vivax malaria and prevent the transmission of falciparum malaria Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Primaquine for vivax and falciparum malaria 

Malaria is an endemic disease in much of the world, and is a major contributor to child and infant mortality in many countries. Our malaria podcasts describe efforts by NDM clinicians and scientists, in Oxford and around the world, to treat and prevent malaria, including vaccine development, parasitology, and improved treatment for severe malaria, with the aim to lessen the disease burden on some of the world's most vulnerable people.

Malaria

Professor Kevin Marsh tells us about his research on Tropical Medicine in Kenya. Professor Kevin Marsh has a broad research interest in child health in the tropics, with a particular focus on the immune epidemiology of malaria. Malaria remains a major world health problem, particularly among children in Africa. Based in Kenya, Professor Marsh is working on preventing and curing malaria in Africa. Professor Marsh is director of the KEMRI Wellcome Programme in Kenya; he also coordinates the malaria immunology group within the programme.

Tropical Medicine in Kenya 

Professor Arjen Dondorp tells us about his work on severe malaria and the development of new therapies. Current malaria therapies using artesunate aim to kill malaria parasites before they mature. Such medications have high success rates but need to be developed further. Based in Bangkok, Thailand, Professor Arjen Dondorp works on the pathophysiology and treatments of severe malaria, antimalarial drug resistance, and improvements in intensive care practice within developing countries.

The treatment of severe malaria 

Dr Simon Draper tells us about his progress in malaria vaccine research. The malaria parasite is a 'master of disguise'. Whilst the development of a vaccine has proved difficult, targeting a pathway for the parasite has led to the neutralisation of all strains of Plasmodium falciparum. Dr Simon Draper's research interests include studies of vaccine-induced malaria immunity and trials of vaccine candidates. Focusing on translational medicine, his group will take their most promising vaccine candidates and manufacture them as clinical grade material; the next step is proof of concept clinical trials in healthy volunteers.

Progress in Malaria Vaccine Research 

Dr Arturo Reyes-Sandoval tells us about his research on a vaccine against Plasmodium vivax. Plasmodium vivax, one of the four malaria parasites that affect humans, is difficult to eradicate due to its ability to lay dormant in the liver for long periods of time. This parasite is found in Africa, Asia, Latin America and the Western Pacific. 40 percent of the world's population is exposed to the disease that is responsible for around 130 to 350 million clinical cases every year. Dr Arturo Reyes-Sandoval aims to develop a novel malaria vaccine against Plasmodium vivax.

Malaria vaccine for P. vivax 

115 years of malaria data collected in Africa gives the most detailed picture yet of where efforts to control malaria infection are being won and lost across the continent. The largest data repository of any parasitic disease in the world, it includes 7.8 million blood samples from more than 30,000 locations in 43 countries. The dataset was collected and analysed by KEMRI-Wellcome Trust researchers based in Kenya, and is the result of over 20 years of research funded by Wellcome.The study shows that sub-Saharan Africa has experienced a decline in the prevalence of P. falciparum – a parasite that causes malaria - from 40% prevalence in children aged 2-10 years old between 1900 and 1929 to 24% prevalence in the same age group between 2010 and 2015. This trend has been interrupted by periods of rapidly increasing and decreasing transmission, thought to be the result of several contributing factors.The study reveals that although previous global initiatives have contributed to an unprecedented decline in infection since 2000, reductions have not occurred uniformly throughout the continent, leaving large parts of West and Central Africa with high transmission rates of the disease.The researchers argue that new tools are needed for the low income and high malaria burden areas of Africa, where gains in malaria reduction have stalled.  The researchers identify several challenges to malaria control, including emerging insecticide and drug resistance, and inadequate funding plans for replacing long-lasting insecticide-treated nets.

115 years of malaria data collected in Africa gives the most detailed picture yet of where efforts to control malaria infection are being won and lost across the continent. The largest data repository of any parasitic disease in the world, it includes 7.8 million blood samples from more than 30,000 locations in 43 countries. The dataset was collected and analysed by KEMRI-Wellcome Trust researchers based in Kenya, and is the result of over 20 years of research funded by Wellcome.<br>The study shows that sub-Saharan Africa has experienced a decline in the prevalence of P. falciparum – a parasite that causes malaria - from 40% prevalence in children aged 2-10 years old between 1900 and 1929 to 24% prevalence in the same age group between 2010 and 2015. This trend has been interrupted by periods of rapidly increasing and decreasing transmission, thought to be the result of several contributing factors.<br>The study reveals that although previous global initiatives have contributed to an unprecedented decline in infection since 2000, reductions have not occurred uniformly throughout the continent, leaving large parts of West and Central Africa with high transmission rates of the disease.<br>The researchers argue that new tools are needed for the low income and high malaria burden areas of Africa, where gains in malaria reduction have stalled.  The researchers identify several challenges to malaria control, including emerging insecticide and drug resistance, and inadequate funding plans for replacing long-lasting insecticide-treated nets.

115 years of malaria in Africa 

The best podcast episodes on physical health. Episodes talk about your diet, sleep, exercise and all the things that people do to improve their physical health and live a healthier life. This topic is for everyone, with applications in all of our everyday lives. Add episodes you're interested into your queue below!

Best Episodes on Physical Health & Your Body

What is this?
1 quote, 3 ideas & 1 question from a carefully curated podcast episode.
Every Monday & Wednesday.

Want a 3rd insight and episode every week? Email me at curation@owltail.com.